Immuneering Corp (IMRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 600K 1.2M 1.8M Q1 '22: 1.5M Q2 '22: 949.8K Q3 '22: 506.1K Q4 '22: 317K Q1 '23: 133.3K Q2 '23: 38.8K Q3 '23: 455 Q4 '23: 0 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Gross Profit TTM

0 250K 500K 750K Q1 '22: 680.7K Q2 '22: 385.8K Q3 '22: 141.7K Q4 '22: 158.8K Q1 '23: 66K Q2 '23: 19.5K Q3 '23: 455 Q4 '23: 0 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q3 '24: -61.8M Q4 '24: -64.1M Q1 '25: -64.2M Q2 '25: -64.1M Q3 '25: -64.2M Q4 '25: -59.4M Q1 '26: -59.2M Q2 '26: -63.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q3 '24: -58.1M Q4 '24: -61M Q1 '25: -61.8M Q2 '25: -62.1M Q3 '25: -62.5M Q4 '25: -56M Q1 '26: -54.4M Q2 '26: -57.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 300K 600K 900K Q1 '22: 834.8K Q2 '22: 564.1K Q3 '22: 364.3K Q4 '22: 158.1K Q1 '23: 67.3K Q2 '23: 19.3K Q3 '23: 0 Q4 '23: 0 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '24: -52.3M Q4 '24: -55M Q1 '25: -53.6M Q2 '25: -51.5M Q3 '25: -50M Q4 '25: -45.3M Q1 '26: -49.7M Q2 '26: -56.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '24: -52.5M Q4 '24: -55.1M Q1 '25: -53.6M Q2 '25: -51.5M Q3 '25: -50M Q4 '25: -45.5M Q1 '26: -49.9M Q2 '26: -57M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '24: 29.4M Q2 '24: 29.7M Q3 '24: 29.8M Q1 '25: 35.5M Q2 '25: 36M Q3 '25: 39.7M Q1 '26: 64.7M Q2 '26: 64.7M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '24: -1.97 Q4 '24: -2.04 Q1 '25: -1.97 Q2 '25: -1.90 Q3 '25: -1.79 Q4 '25: -1.27 Q1 '26: -1.06 Q2 '26: -0.93 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.